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Abstract
The mechanisms by which prenatal events affect development of adult disease are incompletely characterized. Based on
findings in a murine model of maternal transmission of asthma risk, we sought to test the role of the pro-asthmatic
cytokines interleukin IL-4 and -13. To assess transplacental passage of functional cytokines, we assayed phosphorylation of
STAT-6, a marker of IL-4 and -13 signaling via heterodimeric receptor complexes which require an IL-4 receptor alpha
subunit. IL-4 receptor alpha2/2 females were mated to wild-type males, and pregnant females were injected with
supraphysiologic doses of IL-4 or 13. One hour after injection, the receptor heterozygotic embryos were harvested and
tissue nuclear proteins extracts assayed for phosphorylation of STAT-6 by Western blot. While direct injection of embryos
produced a robust positive control, no phosphorylation was seen after maternal injection with either IL-4 or -13, indicating
that neither crossed the placenta in detectable amounts. The data demonstrate a useful approach to assay for
transplacental passage of functional maternal molecules, and indicate that molecules other than IL-4 and IL-13 may mediate
transplacental effects in maternal transmission of asthma risk.
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Introduction
Prenatal events can affect development of certain adult diseases
[1–4], but the mechanisms are not clear. For example, maternal
atopy/allergy can predispose offspring to the development of
asthma [5,6], more so than paternal disease. Moreover, there is
evidence in mice and humans that allergic sensitization may occur
in the prenatal period[7–9]. Our laboratory has developed a
mouse model that recapitulates this ‘maternal effect’[10]. In this
model, offspring of mother mice with ovalbumin (OVA)-induced
asthma develop an asthma-like phenotype (i.e. airway hyperreac-
tivity and airway inflammation) following an ‘intentionally
suboptimal’ asthma induction protocol, whereas offspring of
non-asthmatic mother mice do not. Importantly, this maternal
effect is allergen-independent, since offspring show increased
susceptibility to other allergens besides OVA. This suggests a role
for mediators with broad effects, e.g., cytokines, rather then
specific antibodies.
These data taken together with prenatal sensitization observa-
tions, imply that the in utero environment may be causing increased
asthma risk in offspring. One possible mechanism by which
maternal asthma could cause increased asthma susceptibility in the
developing immune system is the transplacental passage of ‘pro-
allergic’ cytokines.
In addition to providing the fetus with oxygen and nutrients, the
placenta synthesizes and secretes hormones, growth factors, and
cytokines. Moreover, many maternally-derived molecules cross the
placental via a variety of mechanisms [11]. Based on findings in
our mouse model of maternal transmission, we postulated that
passage of pro-asthmatic maternal cytokines could mediate
increased susceptibility of offspring to asthma.
The aim of this study was to characterize a novel assay to assess
for the transplacental passage of functional cytokines, and to use
this technique to assess for passage of the pro-asthmatic/pro-
inflammatory cytokines interleukin 4 and 13 (IL-4 and IL-13)
previously implicated in maternal transmission of asthma risk
[10,12].
Results
In order to devise a functional assay to assess for transplacental
passage of IL-4 and 13, we made use of IL4 receptor alpha
(IL4Ra)2/2 transgenic mice and STAT-6 phosphorylation. IL-4
acts rapidly and primarily through phosphorylation of STAT-6 via
binding to IL-4 receptor type I or II. The type I receptor is a
heterodimer made up of an IL4Ra and gamma-chain subunits.
The type II receptor is made up of IL4Ra and IL-13 receptor
alpha 1 (IL13Ra1) subunits. IL-13 acts through the type I IL-4
receptor. However IL-13 binds to the IL13Ra1 subunit rather
then the IL4Ra subunit (reviewed [13]). Following binding,
STAT6 is phosphorylated, dimerizes, and translocates to the
nucleus. Disruption of the IL-4Ra gene can prevent the
phosphorylation of STAT-6 caused by either IL-4 or 13.
In order to assess if functional IL-4 or 13 can cross the placenta,
this study used female IL4Ra2/2 transgenic mice. These mice
were mated to wild-type males. Thus the resulting embryos were
IL4Ra+/2. On day 20 of pregnancy, the female mice were given
retro-orbital injections of IL-4 or 13. As the mothers were IL-
4Ra2/2, there would be no signaling by the cytokines (i.e.,
phosphorylation of STAT-6) and no downstream effects that
might confuse interpretation (i.e. signaling-induced release of other
mediator(s) which cross the placenta and cause effects rather than
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IL4Ra+/2, they can respond to IL-4 and 13. Thus, if
phosphorylation of STAT-6 is detected in fetal tissue, then the
cytokines would have had to have crossed the placenta in a
functionally intact state to interact with the IL-4Ra present on the
heterozygotic fetal cells. The phosphorylation signal is detectable
by Western blot analysis using a phospho-STAT-6 (P-STAT-6)
antibody.
Injection of IL-4 and IL-13 causes detectable
phosphorylation of STAT-6 in fetal lung nuclear protein
extract, but not total protein extracts
Following retro-orbital (R.O.) or intraperitoneal injection (I.P.)
of IL-4 or IL-13 into wild type adults, Western blot analysis
showed ample phosphorylation of STAT-6 in lung tissue total
protein extracts. Similar results were observed using IL4Ra+/2
adults. Non-injected mice showed no phosphorylation. After
having demonstrated that retro-orbital and intraperitoneal injec-
tions had similar results, further adult mouse injections were all
retro-orbital. We were unable to clearly and consistently detect
phosphorylation of STAT-6 in lung tissue total protein extracts of
directly injected (intraperitoneal injections) embryos (either wild-
type or heterozygote) (not shown). The embryos were given I.P.
injections because retro-orbital injections were not technically
feasible.
In order to increase our ability to detect phosphorylation of
STAT-6, nuclear protein extracts from lung tissue were used. As
STAT-6 is translocated into the nucleus following phosphoryla-
tion, the nuclear fraction of protein is enriched with the
phosphorylated form. Using nuclear protein extracts from lung
tissue, phosphorylation of STAT-6 could be detected following
injection of IL-4 into adult wild-type mice (R.O.) and fetal (I.P.)
IL4Ra+/2 mice (Figure 1, PC1 and PC2, respectively). An
appropriate size band for phosphorylated STAT-6 is seen in both
positive control lanes. No phosphorylation was seen in PBS
injected specimens (Figure 1, NC). Similar data was seen using IL-
13 injections (Figure 2, PC and NC1, NC2). HDAC1 was used a
loading control.
Absence of evidence that IL-4 or IL-13 cross the placenta
Results for the IL-4 maternal injections are summarized in
figure 1. The negative controls were nuclear protein extracts from
pooled lungs from 3 IL4Ra+/2 embryos injected (I.P.) with PBS.
The positive controls were nuclear extracts from lungs of a wild-
type female and pooled lungs from 3 IL4Ra+/2 fetuses injected
with IL-4, respectively. The experimental group consisted of
nuclear protein extracts from pooled lung tissue from 3 IL4Ra+/2
fetuses after maternal injection (R.O.) of IL-4. Maternal injections
were done in a total of 9 pregnant females. Figure 1 shows
representative data from 3 trials. In negative control lanes, no
bands were detected for phosphorylated STAT-6 (Figure 1).
Appropriate size bands were noted in both positive control lanes
(Figure 1). In the 3 experimental lanes, there were no detectable
phosphorylated STAT-6 bands. From this data, it can be
concluded that sufficient functional IL-4 did not cross the placenta.
HDAC1 was used as a nuclear protein loading control.
In a second of set of experiments, IL-13 was injected into
IL4Ra2/2 pregnant females (R.O.). The results were similar to
those found using IL-4. Maternal injections were done in a total of
9 pregnant female. Figure 2 shows representative data from 3 of
the 9 injections. Heterozygote fetuses of injected mothers did not
show phosphorylation of STAT-6, though it was seen in directly
injected (I.P.) heterozygote fetuses (Figure 2). Both negative
controls in figure 2 do not show a band, though NC1 had
significantly less nuclear protein loaded as compared to others.
From this blot, it could be concluded that sufficient functional IL-
13 did not cross the placenta.
Discussion
In order to assess for in vivo transplacental passage of functional
cytokines, we devised a novel technique using IL4Ra2/2 mice.
These female mice were mated with wild-type males, producing
heterozygote embryos. The mothers were injected with supra-
physiologic doses of IL-4 or IL-13, and the nuclear extracts of the
embryonic lungs were analyzed using Western Blot for presence of
phosphorylated STAT-6. Both IL4 and IL13 act via binding to a
receptor heterodimer complex that includes an IL4Ra subunit.
Following binding, Janus family of protein kinases (Jaks) that are
constitutively associated with IL-4Ra are activated. The end result
Figure 1. STAT-6 phosphorylation following injection with IL-4.
Positive control consists of lung nuclear proteins from wildtype adults
(PC1) or IL4Ra+/2embryos directly injected with IL-4 (PC2). Negative
controls consist of lung nuclear protein from IL4Ra+/2 embryos directly
injected with PBS (NC). The experimental group consists of nuclear
proteins from IL4Ra+/2 embryos whose mothers were injected with IL-
4. Bands for P-STAT-6 are only detectable in positive control lanes. No
bands are detected in experimental and negative control lanes. HDAC1
was used a loading control.
doi:10.1371/journal.pone.0004660.g001
Figure 2. STAT-6 phosphorylation following injection with IL-
13. Positive control (PC) consists of lung nuclear proteins from IL4Ra+/
2 embryos directly injected with IL-13. Negative controls consist of
lung nuclear protein from IL4Ra2/2 females injected with IL-13 (NC1)
and nuclear protein from IL4Ra+/2 embryos injected with PBS (NC2).
The experimental group consists of nuclear proteins from IL4Ra+/2
embryos whose mothers were injected with IL-13. Bands for P-STAT-6
are only detectable in PC lane. HDAC1 was used as a loading control.
Insufficient protein was loaded in NC1, but otherwise protein loading
was similar.
doi:10.1371/journal.pone.0004660.g002
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[13]. Because the mothers lacked IL4Ra, and are unable to
phosporylate STAT-6 in response to either IL-4 or 13, then any
phosphorylation of STAT-6 in the heterozygote embryos would be
a result of transplacental passage of functional cytokines. Aside
from these canonical activators of STAT-6, there may also be
some alternative pathways [14]. Some studies have shown that IL-
3 [15], 15 [16], platelet derived growth factor [17], and IFN-
gamma [18] can activate STAT-6, though these experiments were
done in cell lines and may not be relevant to this experimental
model, especially given the negative results.
In order to maximize the likelihood of placental crossing, the
pregnant IL4Ra2/2females in the experimental groups were
injected with supraphysiologic doses of IL-4 and IL-13 (1000 ng).
Based on the lack of phosphorylated STAT-6 found in
heterozygote embryos, it is unlikely that either IL-4 or IL-13
cross the placenta at the dose used. We also interpret the data to
indicate that it is unlikely that either cytokine would cross under
natural conditions as the injected dose was much higher the
normal serum ranges.
It is possible that gestational age at time of cytokine delivery
may affect its transplacental passage, and that at earlier time-
points (i.e. ,20 days gestation) cytokine may be able to cross the
placenta. However studies examining the relationship of gesta-
tional age and placental permeability to cytokines are lacking.
From a practical standpoint, this experimental approach is only
feasible at gestational ages greater than 18 days. At earlier
gestational ages, harvesting of lung tissue becomes problematic.
Due to the size and consistency of the embryo, it is difficult to
reliably isolate sufficient amounts of lung tissue and separate the
heart-lung block. Direct embryonic intraperitoneal injection also
becomes increasingly challenging with earlier gestational ages
making generation of appropriate positive and negative controls
difficult. Hence, this experimental approach may be most useful in
assaying transplacental passage of maternal molecules in the near
term embryo.
Lung tissue is not the only tissue that could have been targeted
for analysis. The lung was chosen as STAT-6 is known to play a
key role in pulmonary eosinophilia and airway hyperreactivity in
the context of experimental asthma [19–21]. Others have also
examined STAT-6 activation in lung tissue[22]. Another easily
accessible target embryonic organ is the liver. In pilot experiments,
we attempted to use liver tissue, however were unable to obtain
clear consistent signal in positive controls, as opposed to in lung
tissue.
Several potential problems to this study merit discussion. The
first is the somewhat arbitrary nature of the 1 hour time point
picked for time from injection of mother until embryo harvest.
This time point was used since in an ex vivo perfusate study
examing transplacental passage of IL-6, evidence for passage was
found in less then 1 hour [23]. Our data do not exclude the
possibility that both or one of these cytokines cross the placenta, in
a process that takes longer then 1 hour. A second potential issue is
the relatively short half-life of phosphorylated STAT-6. In cell
culture studies, the half-life of phosphorylated STAT-6 after a
single bolus dose of IL-4 was less then one hour. However,
phosphorylated STAT-6 persisted much longer with a more
prolonged exposure to IL-4 [24]. It is possible that even if
transplacental passage of IL-4 or 13 occurred, phosphorylated
STAT-6 may have already degraded by the time the embryos
were harvested, leading to a false negative. This seems unlikely as
the positive controls (both embryo and adult) still showed
phosphorylation of STAT-6 at the same 1 hour time point. A
3
rd possible problem is the sensitivity of Western Blot for detection
of phosphorylated -STAT-6. If only a small amount of IL-4 or 13
cross the placenta, then the level phosphorylation may be very low,
and not detectable by Western Blot. While this is a possibility,
given that our positive controls (directly injected ILRa+/2
embryos) showed phosphorylation, this does not seem likely.
The maternal-fetal interface is an immunologically active site
rich in cytokines [25–27]. However, few studies have looked
specifically at the transplacental passage of cytokines. The
published studies use two approaches. The first relies on injection
of radiolabelled cytokines into mothers and assessing the offspring
for radioactivity [28]. The draw back of this approach is that even
if radioactivity is detected in the offspring, it is possible that just a
metabolized fragment of the cytokine containing the radioactive
tag crossed, rather than a functional intact cytokine. The second
type of study is performed by perfusing placentas ex vivo. The
drawbacks of these studies are the technical difficulties and the
arguably non- physiologic system. This approach is also not
practical for mouse studies. Obviously, neither system is ideal.
Moreover, results with these approaches have been quite
variable[23,29–32], with data both supporting (e.g. [23,31]) and
refuting (e.g.[29,30,32]) transplacental passage. The approach
used in this study to assess for transplacental passage of functional
cytokine is a unique extension of r the one other study we found in
the literature that used a similar approach. Use of CSF-1 deficient
mice (csfm
op/csfm
op) demonstrated that heterozygote mothers (+/
csfm
op) could pass sufficient CSF-1 across the placenta to promote
the normal appearance of macrophages in csfm
op/csfm
op
embryos[33]. However, that study did not test for functional
effects directly related to maternally injected cytokines.
Overall, our study illustrates the potential of this functional
approach to evaluate transplacental passage of functional
mediators. This approach does require that mediators in question
operate through a receptor for which viable, reproductively
normal, receptor-deficient mice exist. This is true for many, but
not all, potential molecules of interest. For our maternal
transmission model, we conclude that the data do not support
the postulate that IL-4 and 13 cross the placenta under these
experimental conditions. This result was surprising in that our
previous work implied a key role for maternal IL-4 in the maternal
transmission of asthma risk [10]. That study demonstrated that
maternally injected monoclonal IL-4 antibody could attenuate
offspring asthma susceptibility. The negative finding from this
study has stimulated ongoing studies of other potential mediators,
e.g. stress hormones. Although the results of this study were
negative, this experimental approach using transgenic mice may
be useful in future studies that assess for transplacental passage of
maternal molecules.
Materials and Methods
Male and female BALB/c mice, 8–10 week-old were obtained
commercially from Charles River Laboratories (Wilmington, MA).
IL-4 receptor alpha knockout (IL4RaKO) mice (BALB/c
background) were obtained from Jackson Laboratories (BALB/c-
Il4ra
tm1Sz/J, stock number 003514). Mice were housed and fed
standard lab chow ad libitum in a pathogen-free barrier facility that
was maintained at 22–24uC with a 12-h dark/light cycle. Animal
experiments and husbandry standards were approved by the
Harvard Medical Area Standing Committee on Animals.
8–10 week old female IL4Ra2/2 mice were mated with wild-
type BALB/c mice. At approximately 20 (E20) days post-mating,
the pregnant females were anesthetized with an intramuscular
injection of ketamine/xylazine. Once adequate anesthesia was
obtained, the females were given a retro-orbital injection of IL-4 or
Placental Passage of IL-4&13?
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were euthanized. The heterozygote embryo lungs were harvested
as were the maternal lungs. The lungs were flashed frozen in liquid
nitrogen and stored at 280 degrees C.
For positive and negative controls, a subset of the pregnant
females were processed differently. The E20 females were
anesthetized with ketamine/xylazine. Then a 1 cm incision was
made in the abdomen. The embryos were then exposed. In a litter,
half the fetuses were directly injected (I.P.) with IL-4 or IL-13
(500 ng, positive controls) or PBS (negative controls). The embryos
were then re-inserted into the mothers abdomen. The fetal lungs
were then harvest an hour later. In the interim between injection
and harvest, the mother’s abdominal cavity was periodically
washed with warm (37 degree Celsius) PBS to maintain maternal
temperature and to prevent dessication of the abdominal cavity
and fetuses. At time of harvest, fetuses were confirmed to be alive
by fetal movement prior to euthanasia.
Nuclear protein was extracted from frozen lungs. The tissue was
homogenized in lysis buffer (1.5 mM MgCl2, 10 mM KCl, 0.1%
NP-40, 0.5 nM DTT, Roche complete protease inhibitor (16),
and 10 mM HEPES (pH 7.9)). The lysate was then centrifuged at
900 RCF for 10 minutes at 4 degrees C. Supernatant was removed
and pellet resuspended in the wash buffer. This was centrifuged
again at 1200 RCF for 10 minutes at 4 degrees C. Supernatant
was discard and resuspended in nuclear extraction buffer (1.5 mM
MgCl2, 0.42 M NaCl, 0.2 mM EDTA (pH 8.0), 25% glycerol,
0.5 M DTT, and 20 mM HEPES (pH 7.9)). This was mixed on
an orbital shaker for 30–60 minutes, then spun down at 20,000
RCF for 15 minutes at 4 degrees C. The supernatant, which
constituted the nuclear protein, was then aliquoted and frozen at
280 degrees. This amount of protein was quantified using a
bicinchoninic acid assay (BioRad). Western Blots were performed
using a Tris-Glycine Gel System (Invitrogen). Membranes were
probed using polyclonal antibodies raised against Phospho-STAT-
6 (PSTAT6) and HDAC1 (Santa Cruz Biotechnologies, Cell
Signaling Technologies). Primary antibodies were detected with
HRP conjugated anti-rabbit polyclonal antibody. Bands were
visualized using the ECL+ Western Blotting Detection System
(Amersham) and the Alpha-Innotech gel imager.
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